Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®
Asabys joins SafeHeal’s global investor syndicate, which includes Sofinnova, Solar Eclipse and a Leading Multinational Life Sciences Corporation, bringing additional resources and strategic expertise to advance pivotal U.S. trial and commercial launch of Colovac®, SafeHeal’s breakthrough alternative to temporary stoma for colorectal cancer patients
SafeHeal®, a medical device innovator transforming colorectal surgery, today announced a €10 million extension of its oversubscribed €35 million Series C financing round. The extension is led by Asabys Partners through its Sabadell Asabys II fund, which joins a world-leading syndicate that includes Sofinnova Partners, Solar Eclipse, Gideon Strategic Partners, Polis, M&L Healthcare, and one of the world’s largest multinational life sciences corporations. Gideon Strategic Partners, an existing investor, has also increased its participation in this extension.
The new capital raise will further accelerate SafeHeal’s pivotal U.S. IDE study and support the planned commercial launch of Colovac® in the EU. Colovac is SafeHeal’s groundbreaking temporary endoluminal bypass device, designed to eliminate the need for a temporary stoma in most patients undergoing colorectal cancer resection, improving patient recovery, outcomes and quality of life.
As part of this financing, Josep Ll. Sanfeliu, Managing Partner and co-founder of Asabys, will join SafeHeal’s Board of Directors.
“We are delighted to welcome Asabys Partners as the lead investor in this Series C extension,” said Chris Richardson, President & CEO of SafeHeal. “Their addition strengthens our strategic capabilities in medtech and demonstrates our growing momentum as we advance toward FDA approval and EU commercial launch. We’re equally grateful for the continued support from Gideon Strategic Partners and the entire syndicate of world-class investors.”
Josep Ll. Sanfeliu, Managing Partner and co‑founder of Asabys, commented: “Asabys is an ambitious and fast-growing investment firm committed to supporting world-class healthcare innovation across Europe and beyond. We are proud to join SafeHeal’s investor syndicate, reflecting our belief in both the outstanding team and the transformative impact of Colovac for patients facing colorectal cancer surgery. We look forward to working closely with SafeHeal’s management and our fellow investors to help bring this important technology to patients worldwide.”